BioCryst Pharmaceuticals (BCRX) 10-Q 2008 Q2 Quarterly report

Exhibit 10.25

BIOCRYST PHARMACEUTICALS, INC.
2425 KILDAIRE FARM ROAD, SUITE 106
CARY, NC 27518
919-859-7908 919-859-1314 FAX

2190 PARKWAY LAKE DRIVE
BIRMINGHAM, AL 35244
205-444-4648 205-444-4640 FAX

www.biocryst.com

May 21, 2008

Mr. Stuart Grant
240 Summer St.
Norwell, MA 02061

Dear Stuart,

I would like to present you with this retention bonus program in recognition of the outstanding and valuable contributions you have made to BioCryst Pharmaceuticals and will continue to make in the future. The Compensation Committee has reviewed this program and has approved offering it to you. The retention bonus will be extended and paid to you as long as you remain an active employee with the company through December 31, 2009.

You will be provided with the following retention bonus;

• 80% of your 4/1/08 annual base salary, plus;

• The equivalent of 20% of your 4/1/08 annual base salary in Restricted Stock Awards (24,839 shares of common stock).

As a section 16 Officer, extending this retention bonus to you will be viewed as material and will require an 8-k disclosure. In the event of a Change of Control, prior to December 31, 2009, you will be eligible to receive the benefits as noted above.

Our future success as a company is directly related to your important contributions and ongoing leadership. Once again, thank you for your continued support and help in making BioCryst a financial success.

Sincerely,

/s/ Jon StonehouseJon Stonehouse

CEO and President

BioCryst Pharmaceuticals, Inc.